tiprankstipranks
Dyne Therapeutics (DYN)
NASDAQ:DYN
US Market
Holding DYN?
Track your performance easily

Dyne Therapeutics (DYN) Income Statement

294 Followers

Dyne Therapeutics Income Statement

Last quarter (Q3 2024), Dyne Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Dyne Therapeutics's net income was $-97.13M. See Dyne Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
-----$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 314.47M$ 242.16M$ 170.96M$ 150.03M$ 58.65M$ 13.83M
Operating Income
$ -314.47M$ -242.16M$ -170.96M$ -150.03M$ -58.65M$ -13.83M
Net Non Operating Interest Income Expense
$ 21.08M$ 7.64M$ 2.92M$ 742.00K$ -340.00K$ 290.00K
Other Income Expense
$ -1.42M$ -1.42M$ -54.00K-$ -450.00K$ -1.32M
Pretax Income
$ -294.51M$ -235.94M$ -168.10M$ -149.29M$ -58.54M$ -14.86M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -294.51M$ -235.94M$ -168.10M$ -149.29M$ -58.54M$ -13.54M
Basic EPS
$ -3.57$ -3.95$ -3.23$ -2.93$ -4.13$ -1.31
Diluted EPS
$ -3.57$ -3.95$ -3.23$ -2.93$ -4.13$ -1.31
Basic Average Shares
$ 335.90M$ 59.68M$ 51.98M$ 50.90M$ 14.40M$ 10.32M
Diluted Average Shares
$ 335.90M$ 59.68M$ 51.98M$ 50.90M$ 14.40M$ 10.32M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 314.47M$ 242.16M$ 170.96M$ 150.03M$ 58.65M$ 13.83M
Net Income From Continuing And Discontinued Operation
$ -294.51M$ -235.94M$ -168.10M$ -149.29M$ -59.44M$ -14.86M
Normalized Income
$ -117.09M$ -186.39M---$ -14.86M
Interest Expense
-----$ 0.00
EBIT
$ -314.47M$ -242.16M$ -170.96M$ -150.03M$ -58.14M$ -14.86M
EBITDA
$ -313.82M$ -240.49M$ -169.28M$ -148.94M$ -58.34M$ -14.59M
Currency in USD

Dyne Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis